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Mathematical analysis of immune mechanisms 
in general and of anti-tumor immunity in particu-
lar has a rich intellectual history [1-8]. Predator-
prey equations have seemed to fit the problem 
nicely since the time of Bell [4], and remain sub-
ject of active investigation in the 21st century[2, 
8, 9]. With growth in knowledge about the intri-
cacy of the immune system, complex systems of 
10 to 20 coupled differential equations, often 
nonlinear, have been developed to describe the 
humoral and cellular immune responses, includ-
ing changes in cell populations in response to 
chemical signals arising from hormones, cyto-
kines, and cellular debris [5, 10]. There can be 
separate equations for each subtype of cell and 
for concentrations of relevant chemical media-
tors [5]. Details of the immune system and its 
systematic analysis are reviewed in [3, 5, 7, 10].  
 
Typically mathematical models have dealt with 
anti-tumor immunity directed toward highly anti-
genic tumors arising from a single cell [5, 7]. 
They have shown the conceptual feasibility of 
“tumor surveillance” by the immune system and 
destruction of microscopic nascent tumors of 
high antigenicity. However, there is a need for 
models dealing with established tumors that 
cause clinical cancer, in part because they have 
evaded early tumor surveillance and have 
grown to macroscopic sizes. These tumors, al-
most by definition, are weakly antigenic. The 
theoretical potential for destruction of such lar-
ger, established tumors by treatments that 
boost the immune response, such as adoptive 
cell therapy [11-14], immune-modulating drugs 
[15-18], and anti-cancer vaccinations [19-23] 
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remains a subject of active investigation. 
 
Although complex mathematical models involv-
ing many differential equations can provide use-
ful insights into detailed mechanisms, they suf-
fer from the need to specify a large number of 
parameters. These values are difficult to esti-
mate for cases of human disease, for which 
relevant data are often non-existent. Some pa-
rameter values can be extrapolated from mouse 
and hapten-carrier systems [5, 24], for which 
results are often inconsistent among different 
experiments [7]. Remaining unknown parame-
ters must be set arbitrarily [5]. In this sense 
there is a long leap from lab bench and laptop 
to bedside. Hence there may be virtue in study-
ing less complex mathematical systems, for 
which parameters can be estimated from hu-
man clinical observations and experience, and 
perhaps even individualized to particular mo-
lecular subtypes of cancer in particular types of 
patients [25]. 
 
Accordingly, the goals of the present research 
were to develop a simple and workable mathe-
matical model of immunotherapy directed to-
ward weakly antigenic, macroscopic tumors in 
human beings and to explore theoretical differ-
ences between successful and unsuccessful 
treatment scenarios and protocols. Ideally such 
a model has enough terms to provide a reason-
able approximation of reality but is simple 
enough for its functioning and limitations to be 
fully understood. Here we adopt a classical 
predator-prey formulation of the tumor immunity 
problem as a battle between immune cells and 
tumor cells (predators and prey, respectively). 
We note that the immune system, like an army, 
includes soldiers with many ranks and roles, 
organized into functional units. Although there 
is, without doubt, virtue in detailed analysis to 
understand and exploit mechanisms, there is 
also value in predicting the outcome of a battle 
in broader terms: the comparative sizes of the 
opposing armies and their comparative fighting 
effectiveness. In many cases these factors 
alone are sufficient to predict the outcome as 
an easy victory for one side or the other, or per-






Consider one compartment in which a tumor 
grows autonomously and in which tumor cells 
are killed upon contact with cytotoxic immune 
cells (immunocytes, including lymphocytes and 
activated macrophages). Let T denote the num-
ber of tumor cells and let L denote the number 
of immune cells. The time rate of change in tu-
mor cell numbers (dT/dt) is increased by cell 
division and diminished by first-order spontane-
ous cell death, supplemented to a varying de-
gree by immune mediated cell killing. The rate 
of change in anti-tumor immune cells (dL/dt) is 
driven by signals arising from the interaction, 
represented by the product, TL, of existing tu-
mor cells, T, and immune cells, L. Immune cells 
also experience half life decay from death and 
emigration. The corresponding model equations 
as a function of time, t, are 
 




                                 (1b)  
 
Equation (1a) has the general structure dT/dt = 
net replication rate in absence of tumor immu-
nity – rate of killing by immunocytes. Equation 
(1b) has the general structure dL/dt = recruit-
ment from cell-cell signaling – half life removal.  
 
Constants, g, k, , and μ are lumped parameters 
representing the overall effectiveness of compo-
nent processes.  Constant, g, represents net 
tumor cell growth minus decay. That is, g = g1 – 
g2, where g1 is the first order rate constant for 
cell division, and g2 is the first order rate con-
stant for spontaneous tumor cell death caused 
by processes other than immune mediated kill-
ing. Constant, k, represents the average killing 
effectiveness of all immune effector cells, L, 
that is, an average soldier in the army, including 
those in non-combat roles. Constant, , repre-
sents positive feedback on lymphocyte recruit-
ing. The positive feedback may result from re-
lease of tumor antigens or from release of cyto-
kines by active lymphocytes. The half life decay 
of immune cells, L, is denoted μ, representing 
spontaneous death and emigration. Modeling 
tumor cell killing by immune cells in expression 
(1a) as kL, rather than a more traditional formu-
lation [1], such as kLT or kLT/(K+L), enhances 
simplicity and may be more reflective of non-
random targeting of tumor cells by lymphocytes. 
Such purposeful targeting would tend to make 
killing rates proportional to the number of lym-
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time killing abruptly ends. 
 
Initial conditions describe the state of the tumor 
at the time of diagnosis. T0 is the initial pre-
treatment tumor cell population. L0 is the initial 
immune cell population within the tumor com-
partment, where L0 << T0 in un-rejected and 
clinically troublesome tumors. To normalize for 
various sizes of tumors at the time of diagnosis 
(Others have modeled different growth rates 
and cytokinetics for tumors of grossly different 
size, ranging from one nascent cell to 107 or 
more cells. Here the size range is much more 
restricted to tumors the size that come to clini-
cal attention, say ~ 1 to 100 ml at diagnosis, in 
which case it is reasonable to consider a single 
clinical growth rate at this stage.), let y = T/T0 
represent the relative tumor size, and let x = L/
T0 represent the relative immune cell density 
within the tumor. Then 
 
 
                                (2a) 
 
  
             (2b)  
 
where the new constant, λ = T0, describes the 
net effects of positive feedback signaling. The 
initial conditions for equations (2) are y0 = 1, 
representing the size of the tumor at diagnosis, 
and x0, representing the initial immune cell den-
sity, as determined for example by quantitative 
microscopic analysis, flow cytometry, or histo-
chemistry of excised tumors or biopsy speci-
mens. Here the rate of change in immunity is 
influenced by four factors: net spontaneous 
growth of the tumor, g, tumor killing ability of 
immunocytes, k, the ability of immunocytes, λ, 
to call for help and increase their numbers in 
the battle space, and the spontaneous rate, μ, 





When t = 0, then y0 = 1, and when k = 0 (no 
tumor cell killing), y = egt with unopposed tumor 
growth. When λ = 0 and k ¹ 0 there is tumor cell 
killing by the original L0 lymphocytes only, but 
no recruiting of additional immune cells. In this 
case, the immunocytes decay exponentially so 
that x = x0e-μt, and in turn, dy/dt = gy - kx0e-μt, 
showing slower growth than the unrestricted 
case, because of time limited tumor killing ini-
tially. 
 
Mid-range, reference parameters 
 
A most interesting and useful case is that of an 
unstable steady-state, in which the tumor nei-
ther grows nor shrinks in size. This condition 
represents a stalemate in which neither the 
immune system or the tumor gains the upper 
hand and is a useful starting point for theoreti-
cal explorations of strategies and effects. In this 
case we have  
 
 
and y0 = 1, so that k0=g/x0.  (3) 
 
 
Also, in the steady state we must have no net 
change in immune cell numbers, hence 
  
so that λ0 = μ.      (4) 
 
 
These equilibrium values of k0 and λ0 represent 
the middle of the biologically relevant domain of 
immune system activity. Their numerical values 
can be estimated from clinical observations in 
terms of g, x0, and μ as follows, to obtain a start-
ing point for simulations. 
 
Parameter estimation for conditions prior to 
treatment 
 
Estimation of g 
 
Rates of disease progression in patients with 
the same type of cancer vary, even among can-
cers of the same cell type and stage. Suppose 
that average tumors are held in check, com-
pared to more aggressive ones, at least partially 
by immune mechanisms. This state of affairs is 
suggested by clinical data on the emergence of 
tumors during immune-suppressive therapy for 
organs transplants [26, 27], and also by the 
correlations of tumor associated lymphocyte 
numbers with clinical prognosis [28-30]. In this 
case one can estimate the unrestricted growth 
rate, g, from the doubling time of more rapidly 
progressing tumors in a given class. For mini-
mally immunogenic tumors dy/dt ≈ gy, or dy/y ≈ 
gdt, from which, after integration, y ≈ egt. For 
doubling time t2, it follows that 2 ≈ egt2, or g ≈ ln
(2)/t2 ≈ 0.69/t2. For example, if more aggres-
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170 days after diagnosis, then we would have g 
= 0.004 days-1. 
 
Estimation of x0 
 
Parameter x0 can be obtained from biopsies of 
human tissue, as determined by quantitative 
microscopic analysis, flow cytometry, or histo-
chemistry of excised tumors or biopsy speci-
mens. Microscopically detectable lymphocytes 
are rare but detectable in many tumors [28-30], 
suggesting a relative density on the order of 
1/1000. 
 
Estimation of k0 
 
For the equilibrium condition (3) we must have 
k0 = g/x0. For example, if g = 0.004 days-1, x0 = 
0.001, this implies k = 4 tumor cells killed per 
lymphocyte per day. From considerations of 
practical biology a lymphocyte can only kill a 
handful of tumor cells per day [5]. Hence values 
of 1 < k < 10 are quite reasonable. 
 
Estimation of μ 
 
Normal biology and clinical experience set limits 
on the value of lymphocyte decay, μ. The offset 
time for moderate to severe viral infections, 
which are combated by cellular immunity, is on 
the order of a few days or about one week. The 
exponential decay of the induration of a PPD 
(purified protein derivative) test for tuberculosis, 
also mediated by cellular immunity, is also a few 
days to one or two weeks [31]. Thus in the ab-
sence of stimulation (λxy = 0) we would have 
dx/dt = –μx or , x ≈ e-μt . For half time t1/2, it fol-
lows that 1/2 ≈ e-μt1/2, or μ ≈ ln(2)/t1/2 ≈ 0.69/
t1/2. For example, if the offset of a cellular im-
mune response has a half life of 7 days, then μ 
≈ 0.1 days-1. 
 
In this way mid-range orders of magnitude for 
parameters g, x0, and μ, and in turn k0, and λ0 
can be determined from clinical data. It is not 
necessary to have expensive equipment, animal 
models, cell cultures, large laboratories, or 




Equations (2) were integrated numerically using 
the simple Euler method implemented in Visual 
Basic code within an Excel spreadsheet on an 
ordinary personal computer. Optionally, neces-
sary computations can be done within spread-
sheets themselves using only arithmetic func-
tions. For 
 






Given initial conditions at t = 0, one can trace 
the evolution of the variables x and y in time, in 
a “marching solution”, for which stability and 
accuracy are ensured by using a sufficiently 
small value of Δt, such as 0.01 day. Increasing 
or decreasing Δt without effect on the results 
confirms that a sufficiently small value was cho-




Consider a hypothetical human tumor, such as 
a basal cell carcinoma of the skin, having prop-
erties shown in Table 1, estimated from clinical 
observations, as just described. 
Figure 1A illustrates changes in tumor size as a 
function of time as the cell signaling parameter, 
λ, is increased from the steady-state value of 
0.1 days–1. The horizontal axis for this model 
represents 2000 days or about 5.5 years. For 
simplicity, we assume that average tumor 
growth rate, g, is not affected by immunother-
apy and that the tumor cells are equally suscep-
tible to cytotoxic cells. The dashed horizontal 














y0 1 Relative tumor cell 
count or size 
x0 0.001 Relative density of 
immune cells 
g 0.004 days-1 Unopposed tumor 
growth constant in  
y = y0egt 
k 4 days-1 Immune cell killing 
effectiveness tumor 
cells/lymphocyte/day 
λ 0.1 days-1 Immune cell signal-
ing constant lympho-
cytes/tumor cell/day 
μ 0.1 days-1 Decay constant for 
immunocytes in  
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librium, in which immune mediated tumor cell 
killing exactly balances spontaneous tumor 
growth. A 10 percent increase in λ produces an 
initial decline in tumor cell numbers, followed by 
three cycles of re-growth, and then a precipitous 
population crash with tumor elimination. Oscilla-
tory patterns are consistent with classical 
swings in predator-prey populations [1, 4]. 
Sharper and earlier population declines happen 
as λ approaches 1.7 times the steady state 
value. However, late re-growth to more than 
double the original volume occurs before the 
tumor is eliminated by the immune response. 
Late recurrences at 2 to 5 years for λ near 0.17 
are characteristic of many cases of clinical can-
cer. The recurrences in Figure 1A, however, are 
not caused by tumor escape mechanisms, tu-
mor cell heterogeneity, or evolution of tumor cell 
resistance [32, 33]. Instead they result solely 
from the dynamics of the predator-prey system 
with a constant state of immune system activa-
tion. In all cases shown the tumor is eventually 
destroyed when cell signaling, λ, is increased 
above the steady-state equilibrium value. 
 
When cell signaling effectiveness, λ, is 0.18 or 
greater (filled circles) there is steady decline of 
tumor cell numbers to zero, with complete and 
irreversible elimination of the tumor. There ap-
pears to be a threshold near λ = 0.18, which 
when crossed causes tumor population to crash 
promptly without oscillation. When λ = 0.179 
(open circles) there is late re-growth. However, 
when λ = 0.181 there is complete and perma-
nent tumor elimination. The difference in λ be-
tween the steady-state with λ = 0.1 and highly 
effective therapies with λ > 0.18 is less than a 
factor of two. The trajectory of tumor elimination 
in three months for λ = 0.19 is illustrated in Fig-
ure 1B. 
 
Some interesting and counterintuitive dynamic 
phenomena happen when the cell signaling 
parameter, λ, is reduced from its unstable equi-
librium value of 0.1 day-1, as shown in Figure 
2A. Here, progressive weakening of cell signal-
ing causes accelerated tumor growth initially, as 
would be expected. However, with continuing 
nonzero values of feedback, λ, and normal, ac-
tive immune mechanisms, the tumor size even-
tually reaches a threshold at which the tumor 
cell population crashes to zero, with complete 
tumor elimination. The cost of this indirect strat-
egy is that more tumor growth is needed to trig-
ger or provoke an intense anti-tumor immune 
response. This phenomenon is explained by the 
dependence of dx/dt on the product (LT or xy) of 
both tumor and immunocyte population num-
bers. Yet such dependence is what would be 
expected from the biology of immunity in gen-
eral. The antigen dose matters in provoking ef-
fective anti-tumor immunization [34]. Bacterial 
infections, similarly, must reach a certain size 
before attracting large numbers of inflammatory 
cells. The immunocyte population peaks in Fig-
ure 2B demonstrate responsiveness of the sys-
Figure 1. A. Tumor growth and decay with departure of cell signaling parameter, λ, from its equilibrium value in the 
positive direction for the primary model in Table 1. B. Effective tumor elimination in three months with λ = 0.19, less 
than twice the equilibrium value. 
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tem to increasing cell numbers. Relatively large 
changes in immune cell numbers occur in re-
sponse to relatively modest changes in tumor 
size. The combined results in Figure 2 suggest 
the potential robust nature of anti-tumor immu-
nity. 
 
Figures 3 and 4 illustrate similar time trajecto-
ries of tumor population numbers for depar-
tures of the model parameters k and x0 from the 
unstable equilibrium state. The patterns of tu-
mor growth and regression are quite similar to 
those for manipulations of cell signaling 
strength, λ. Both stronger and weaker cell killing 
effectiveness can lead to tumor elimination, 
preceded in some cases by one or more oscilla-
tions in population numbers. As before, the ro-
bustness of the tumor immunity system is high-
lighted by the large range of cases in with com-
plete tumor elimination can happen, provided 
one is willing to tolerate some initial tumor 
growth.  
Figure 2. A. Tumor growth and decay with departure of cell signaling parameter, λ, from its equilibrium value in the 
negative direction for the primary model in Table 1. B. Time domain trajectories of relative immune cell number, x = 
L/T0, for the case λ = 0.09, showing classical peaks in response to increasing tumor cell numbers. 
Figure 3. A. Tumor growth and decay with departure of killing parameter, k, from its equilibrium value in the positive 
direction for the primary model in Table 1. B. Tumor growth and decay with departure of killing parameter, k, from its 
equilibrium value in the negative direction for the primary model in Table 1. 
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The range of variation in killing effectiveness, k, 
needed to demonstrate the various dynamic 
behaviors, however, is much greater than the 
range of variation in cell signaling, λ. Order of 
magnitude increases in k (and also x0) are 
needed to produce similar qualitative effects as 
achieved by the doubling of λ. However, similar 
patterns appear. When killing parameter k is 
increased from the equilibrium state there is an 
initial fall in tumor cell numbers. However, 
smaller increases in k that are insufficient to 
produce tumor elimination directly are followed 
by oscillations of increasing amplitude until at 
killing threshold is reached. The killing threshold 
is lower for larger values of k. Ultimately, as k is 
increased further, the threshold tumor size is 
exceeded under the initial conditions. On the 
other hand, if k is diminished, tumor growth 
must occur before conditions develop that pro-
voke a lethal trajectory for the tumor. Interest-
ingly, extreme departures of k from its equilib-
rium value in either direction can provoke 
prompt tumor elimination. The cost in the case 
of weaker tumor cell killing is an approximate 
doubling of the original tumor volume before a 
population crash. 
 
A similar phenomenon happens in Figure 4 
when pre-existing immune cell numbers are 
altered at time zero. In the thought experiments 
represented here we assume equilibrium condi-
tions for the primary model with x0 = 0.001, 
representing one immune cell for every one 
thousand tumor cells. Then at time zero the 
number of immune cells is abruptly changed to 
a different value, either greater or less than 
0.001. For example with adoptive immunother-
apy [13, 14] the value of anti-tumor immune 
cells could be suddenly increased. Alternatively, 
a form of treatment that happened to be toxic to 
immune cells locally but not to tumor cells could 
have the opposite effect. After time zero im-
mune cell numbers are free to change in re-
sponse to cell signaling and half life decay. 
 
A greater than 10 fold increase in initial immu-
nocyte numbers is required to produce com-
plete tumor eradication, starting at the equilib-
rium state. Amazingly, a strategy of selectively 
reducing immune cell numbers for a short time, 
provoking an initial burst of tumor growth, also 
seems to be effective in triggering tumor eradi-
cation. This concept of a strategic retreat, as if 
drawing the enemy out, followed by a vigorous 
counterattack, is far from intuitive in clinical 
oncology, but is suggested as a possible win-
ning strategy by the mathematics. Such a strat-
egy may not be as outlandish as it may at first 
seem. For the scenarios in Figure 4B, in which 
tumor growth is required before tumor elimina-
tion, tumor cell numbers reach no more than 4 
times that at the time of diagnosis. Thus a 1 cm 
diameter tumor mass need grow only to the 
cube root of 4 or 1.6 cm diameter before condi-
tions are ripe for its elimination. In many clinical 
situations this would be an acceptable amount 
Figure 4. A. Tumor growth and decay with departure of immunocyte density, x0, from its equilibrium value in the posi-
tive direction for the primary model in Table 1. B. Tumor growth and decay with departure of immunocyte density, x0, 
from its equilibrium value in the negative direction for the primary model in Table 1. 
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of continued growth, if one had some assurance 





Immunotherapy is appealing because immune 
cells efficiently kill target cells with minimum 
destruction of normal neighboring cells. How-
ever, the time course of immunotherapy is 
unlike that of conventional chemotherapy. Tu-
mor killing happens quickly at the end of the 
treatment period, rather than gradually over 
time. With immunotherapy time is required to 
recruit sufficient numbers of cytotoxic lympho-
cytes and their allies before the still dividing 
tumor cells are actively destroyed. A very small 
population of initial lymphocytes can be suffi-
cient to start a positive feedback cycle that ulti-
mately results in tumor elimination, provided 
sufficient time is allowed for immune cell re-
cruitment. Indeed, tumor elimination seems 
quite possible via a variety of strategies that 
manipulate parameters describing the balance 
of power in a predator-prey system.  
 
The complex, and sometimes unexpected, be-
havior of predator-prey systems describing anti-
tumor immunity has been noted by others [5-8]. 
Here we describe several interesting dynamical 
phenomena, including oscillations in tumor cell 
numbers, sharp thresholds between failed and 
completely successful therapy, improved suc-
cess after weakening of anti-tumor response 
parameters, initial tumor growth as a prelude to 
early tumor elimination-even the potential utility 
of deliberately provoking tumor growth in the 
presence of a functioning immune system as a 
strategy for long term cure. 
 
Focusing on the simplest possible predator-prey 
equations for tumor immunity can help to pro-
vide understanding of the relevant cell-cell inter-
actions and their various counterintuitive twists. 
With only two equations, two variables, four pa-
rameters, and reasonable initial conditions one 
can begin to reconstruct the chains of causation 
leading to growth, oscillations, or decay in cell 
population numbers. The phenomena described 
here are not related to evolution of resistance, 
escape mechanisms, or any changes in tumor 
biology. They are simply the result of predator-
prey dynamics. The clinically oriented mathe-
matical models of Equations (1) and (2) may 
help to make such dynamics easier to recognize 
and also easier to exploit in human cancers. 
 
Adoptive immunotherapy [6, 13, 14], for exam-
ple, can be represented by a boost in x0 at the 
beginning of treatment. Drug therapy with im-
mune modifiers such as imiquimod [18] can be 
represented by a boost in λ. Conventional 
chemoradiation treatment can be represented 
approximately by replacing the positive growth 
constant, g, with g = –g. Each cell cycle would 
then lead to death rather than duplication of the 
dividing cell. (Strictly, if g = g1 –g2 , then g = –
(g1 + g2)) Modifying parameters g, k, μ, and λ in 
a systematic way over time can be done to 
simulate combined treatment protocols, includ-
ing various sequences of conventional chemo-
therapy or radiation, followed by immunother-
apy [35, 36], targeted radiation to specific tu-
mor masses that spares systemic damage to 
the patient’s immune system, possible dose 
fractionation schemes, occasional drug holi-
days, etc. Initial estimates of model parameters 
for a particular type of cancer can be refined on 
the basis of ongoing clinical experience in a 
particular practice setting. 
 
The robust nature of anti-tumor immunity sug-
gested by Figures 1 through 4, illustrating the 
wide range of conditions resulting in complete 
tumor elimination, is contrary to the past repu-
tation of immune therapy for cancer as being hit 
or miss, only occasionally successful, inconsis-
tent, and most suitable as a last ditch effort 
when traditional treatments fail [11, 12, 37]. 
However, the same modeling results can help to 
explain how thoughtful observers could have 
reached such conclusions. Equations (1) and (2) 
imply that it is necessary to maintain consistent 
immune stimulation for up to several years and 
in many cases to tolerate noticeable tumor 
growth before a killing threshold is reached. 
Based upon experience with conventional che-
motherapy, however, oncologists would tend to 
interpret continued tumor growth as a sign that 
immunotherapy is not working, and it would be 
discontinued. Early discontinuation of immune 
therapy would clearly lead to failure, providing 
evidence that such therapy is not effective. 
Mathematical models suggest that continued 
growth of the tumor may be necessary for im-
mune therapy to work, so that the product xy or 
LT reaches a critical threshold. Thus predator-
prey modeling may have a positive conceptual 
or intellectual impact by justifying patience and 
inhibiting the human impulse to stop immune 
Mathematical model for immunotherapy  
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therapy too early. 
 
Simplified predator-prey models may be espe-
cially useful if parameter estimation can be cus-
tomized for particular types of human cancer, 
for subpopulations of cancer patients with a 
particular cell type and stage of cancer, or per-
haps even for individual patients. Sophisticated 
and expensive research personnel and equip-
ment are not needed to estimate parameters g, 
k, λ, x0, and μ in Equations (2). Astute clinical 
observations, a calendar, and routine histopa-
thological observations available in most hospi-
tals are all that is needed. Both the model and 
the parameter estimation techniques are easily 
adapted to various human cancers that evoke 
an immune response. 
 
Address correspondence to: Dr. Charles F Babbs, 
Department of Basic Medical Sciences, 1246 Lynn 
Hall, Purdue University, West Lafayette IN47907-
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